Federal contract award
75A50122C00017
THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES PRECLINICAL, REGULATORY, AND MANUFACTURING DEVELOPMENT ACTIVITIES.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $5.3M |
| Current contract value | $5.3M |
| Potential contract value / ceiling | $5.9M |
| Start date | Mar 18, 2022 |
| Current end date | Dec 31, 2026 |
| Potential end date | Dec 31, 2026 |
| Latest award activity | Aug 26, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 7 of 7 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 26, 2026 | P00006 | $0 | THE PURPOSE OF THIS NO-COST UNILATERAL MODIFICATION IS TO APPOINT NEW PRIMARY AND ALTERNATE CONTRACTING OFFICER REPRESENTATIVE'S. THESE ADMINISTRATIVE CHANGES DO NOT AFFECT THE CONTRACT REQUIREMENTS, PERIOD OF PERFORMANCE, FUNDING, OR TOTAL C |
| May 6, 2026 | P00005 | $630.0K | MODIFICATION TO PROVIDE SUPPLEMENTAL FUNDING IN THE AMOUNT OF $630,000.00 FOR CLIN 0004 AND EXTEND THE PERIOD OF PERFORMANCE TO 31 DEC 2026 AND INCORPORATE FY2024 FINAL INDIRECT RATE AGREEMENT. |
| Apr 8, 2025 | P00004 | $1.2M | EXERCISE OPTION 1 CLIN 0004. ADD ALTERNATE COR, REVISE SOW, AND ADD REQUIRED FAR BASED CLAUSES REVISED BY EXECUTIVE ORDERS. |
| Nov 15, 2024 | P00003 | $0 | NO-COST MODIFICATION IS TO: 1) REVISE SECTION B.2 BASE PERIOD OF PERFORMANCE FROM 3/18/2022-3/18/2024 TO 3/18/2022-12/31/2025, 2) REVISE SECTION B.3 OPTION PERIODS TABLE, 3) REVISE SECTION G.2 CONTRACTING OFFICER REPRESENTATIVE, 4) REVISE ATTACHMENT |
| Jun 1, 2023 | P00002 | $0 | THE PURPOSE OF THIS NO-COST MODIFICATION IS TO REVISE KEY PERSONNEL AND EXTEND THE BASE PERIOD OF PERFORMANCE. |
| Dec 12, 2022 | P00001 | $0 | NO-COST MODIFICATION IS TO REVISE THE BUYER AND THE CONTRACTING OFFICER, WITHIN THE PRISM CONTRACT WRITING SYSTEM. |
| Mar 16, 2022 | 0 | $3.5M | THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES PRECLINICAL, REGULATORY, AND MANUFACTURING DEVELOPMENT ACTIVITIES. |
Estimated positioning window
Oct 25, 2026 – Jan 23, 2027
65/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 65/100. Available recorded signals: 60 points.
- Contract end 2026-12-31 (67 days from calculation)
- +35 points
- 2 historical awards in this buyer and category group
- +10 points
- 7 recorded award transactions
- +10 points
- Latest award action: 2026-08-26
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.